BIOLASE (NASDAQ:BIOL) Earns Sell Rating from Analysts at StockNews.com

StockNews.com assumed coverage on shares of BIOLASE (NASDAQ:BIOL) in a report released on Sunday morning. The firm issued a sell rating on the medical technology company’s stock.

BIOLASE Stock Performance

Shares of BIOL opened at $0.01 on Friday. The business’s 50 day moving average is $0.01 and its 200 day moving average is $0.02. BIOLASE has a 12-month low of $0.02 and a 12-month high of $1.94. The company has a market capitalization of $330,729.30, a PE ratio of 0.00 and a beta of 0.67.

About BIOLASE

BIOLASE, Inc, together with its subsidiaries, develops, manufactures, markets, and sells laser systems for dental practitioners and their patients in the United States and internationally. Its dental laser systems allow dentists, periodontists, endodontists, pediatric dentists, oral surgeons, and other dental specialists to perform a range of minimally invasive dental procedures, including cosmetic, restorative, and complex surgical applications.